LEXINGTON, Mass., March 2, 2016 /PRNewswire/ -- scPharmaceuticals, Inc., announced today that the pivotal trial for its ceftriaxone program met the targeted end-points. The primary end-point for the study is non-inferior antimicrobial coverage when compared to the same dose given by intravenous infusion. Antimicrobial coverage refers to time over the Minimum Inhibitory Concentration (MIC), a generally accepted measure of the adequacy of plasma levels of an antibiotic for treatment of infections due to susceptible bacteria.
DySIS Colposcope to be incorporated into national cervical screening programme
EDINBURGH, Scotland--(BUSINESS WIRE)--DySIS Medical Ltd. (DySIS) today announces that it has signed a multi-million pound contract with medical technology distributor, ITEM Medical Technologies as part of the national cervical screening programme in Turkey. No financial details have been disclosed.
CERAMENT™|G 5 mL to be utilized for infection management and prophylaxis in diabetic foot procedures and small extremities
Lund, Sweden, (PRNEWSWIRE) March 1, 2016 – BONESUPPORT™, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced an extension to the CERAMENT™|G product portfolio, adding a 5 mL volume to further develop the management of osteomyelitis (OM) and infection prophylaxis in diabetic foot and small extremities. CERAMENT™|G, which releases Gentamicin, received CE-mark in 2013, and is the first injectable antibiotic eluting bone substitute indicated to promote and protect bone healing in the management of bone infection. CERAMENT™|G is now available in 5 mL and 10 mL in CE-mark countries.
|Forrige 1 2 3 4 5 6 7 8 9 10 Næste 10 Næste|